Form 4: UroGen Pharma Director Leana Wen Acquires Stock Options
SEC Form 4 Filing
Director Leana Wen acquired stock options for 10,000 UroGen Pharma Ltd. ordinary shares on August 6, 2024.
Summary
- On August 6, 2024, Leana Wen, a director of UroGen Pharma Ltd., acquired stock options to purchase 10,000 ordinary shares.
- The exercise price of the stock options is $15.16.
- The options vest in equal quarterly installments over one year, contingent upon continuous service as a director.
- The expiration date for these options is August 6, 2034.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of stock option grants to a director, which is a common practice.
Industry Context
This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 08/06/2024 | Date of transaction: Leana Wen acquired stock options. |
| 08/06/2034 | Expiration date of the stock options. |
| 08/07/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.